You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 20, 2024

Claims for Patent: 8,748,113

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,748,113

Title:	Methods for detecting and monitoring circulating cancer stem cells
Abstract:	Provided herein are compositions, methods, and kits useful for detecting whether a subject has or is likely to develop a cancer and for monitoring, staging and examining a cancer patient. Also provide herein are methods for screening compounds.
Inventor(s):	Matsui; William (Baltimore, MD), Jones; Richard J. (Baltimore, MD), Huff; Carol A. (Ellicott City, MD)
Assignee:	The Johns Hopkins University (Baltimore, MD)
Application Number:	12/743,180
Patent Claims:	1. A method for monitoring the effectiveness of a cancer treatment in a patient, wherein the cancer treatment is for leukemia, comprising the steps of: (a) obtaining a blood sample from the patient; (b) isolating a predetermined population of cells from the blood sample, wherein the isolated cells are CD34.sup.+ and CD38.sup.-, using at least one of flow cytometry, fluorescence activated cell sorting, antibody-dependent depletion, antibody-dependent solid phase capture, panning, affinity column separation, and magnetic selection; (c) determining whether the isolated cells are ALDH.sup.+; and (d) comparing the number of ALDH.sup.+ cells with the number of ALDH.sup.+ cells determined at an earlier time in the cancer treatment. 2. A method for monitoring the effectiveness of a cancer treatment in a patient, wherein the cancer treatment is for multiple myeloma, comprising the steps of: (a) obtaining a blood sample from the patient; (b) isolating a predetermined population of cells from the blood sample, wherein the isolated cells are CD138.sup.-, CD27.sup.+, CD19.sup.+ and CD20.sup.+, using at least one of flow cytometry, fluorescence activated cell sorting, antibody-dependent depletion, antibody-dependent solid phase capture, panning, affinity column separation, and magnetic selection; (c) determining whether the isolated cells are ALDH.sup.+; and (d) comparing the number of ALDH.sup.+ cells with the number of ALDH.sup.+ cells determined at an earlier time in the cancer treatment. 3. The method of claim 2, wherein the isolated cells are also CD52.sup.+. 4. The method of claim 2, wherein the isolated cells are also CD34.sup.-. 5. A method for monitoring the effectiveness of a cancer treatment in a patient, wherein the cancer treatment is for Non-Hodgkin's lymphoma, comprising the steps of: (a) obtaining a blood sample from the patient; (b) isolating a predetermined population of cells from the blood sample, wherein the isolated cells are CD19.sup.+ and CD20.sup.+, using at least one of flow cytometry, fluorescence activated cell sorting, antibody-dependent depletion, antibody-dependent solid phase capture, panning, affinity column separation, and magnetic selection; (c) determining whether the isolated cells are ALDH; and (d) comparing the number of ALDH.sup.+ cells with the number of ALDH.sup.+ cells determined at an earlier time in the cancer treatment. 6. The method of any one of claims 1-5, wherein the cancer treatment is a stem-cell targeted therapy, induction of terminal differentiation, inhibition of telomerase, inhibition of developmental signaling pathways, inhibition of intracellular signal transduction pathways, induction of active immunity to cellular antigens, induction of passive immunity to cellular antigens, a hedgehog inhibitor, a cytotoxic agent, an antiproliferative agent, a targeting agent, a biologic agent, rituximab, alemtuzumab, or an HDAC inhibitor. 7. The method of claim 6, wherein the targeting agent is a kinase inhibitor or a cell cycle regulator. 8. The method of claim 6, wherein the biologic agent is a cytokine, vaccine, viral agent, or immunostimulant.

Details for Patent 8,748,113

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	11/26/1997	⤷ Try a Trial	2027-11-15
Idec Pharmaceuticals Corp.	RITUXAN	rituximab	Injection	103737	02/19/2002	⤷ Try a Trial	2027-11-15
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	05/07/2001	⤷ Try a Trial	2027-11-15
Genzyme Corporation	LEMTRADA	alemtuzumab	Injection	103948	11/14/2014	⤷ Try a Trial	2027-11-15
Genzyme Corporation	CAMPATH	alemtuzumab	Injection	103948	10/12/2004	⤷ Try a Trial	2027-11-15
Genentech, Inc.	RITUXAN HYCELA	rituximab and hyaluronidase human	Injection	761064	06/22/2017	⤷ Try a Trial	2027-11-15
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.